# Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

> **NCT07335328** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 24 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** 1 X 10^6 cells/kg
- **BIOLOGICAL:** 2.5 X 10^6 cells/kg
- **BIOLOGICAL:** Dose expansion: The maximum tolerated dose of CAR-T cells

## Key facts

- **NCT ID:** NCT07335328
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2031-05-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07335328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07335328, "Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07335328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*